NAGE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Niagen Bioscience Inc (NAGE) is not a strong buy for a beginner investor with a long-term strategy at this moment. While the company shows growth in revenue and a strong gross margin, the significant drop in net income and EPS, coupled with a lack of strong positive catalysts or trading signals, makes it prudent to hold off on investing for now.
The MACD is positive and expanding, indicating a bullish trend. RSI is neutral at 67.321, and moving averages are converging, suggesting no strong directional trend. The stock is trading near its R1 resistance level of 4.792 in pre-market, which may act as a short-term barrier.
Revenue increased by 16.19% YoY in Q4 2025, and gross margin improved by 2.66% YoY, indicating operational efficiency. Analyst maintains a Buy rating with a price target of $13, showing confidence in the company's core and injectable business potential.
Net income dropped by 42.44% YoY, and EPS fell by 44.44% YoY, signaling profitability challenges. No recent news or significant insider or hedge fund activity. Congress trading data is also absent, and the stock has a 50% chance of declining in the next month.
In Q4 2025, revenue grew to $33.84M, up 16.19% YoY, but net income dropped to $4.13M, down 42.44% YoY. EPS also declined to 0.05, down 44.44% YoY. Gross margin improved slightly to 64.14%, up 2.66% YoY, showing some operational strength despite profitability issues.
Canaccord analyst Susan Anderson lowered the price target from $14 to $13 but maintained a Buy rating, citing strong demand in the core business and potential upside in the injectable business.
